NCT04577807View on ClinicalTrials.gov

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
Melanoma
Interventions
BIOLOGICAL

Lerapolturev

Lerapolturev administered via direct lesion injection

BIOLOGICAL

Anti-PD-1 Checkpoint Inhibitor

Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions

Trial Locations (12)

15213

University of Pittsburgh Hillman Cancer Center, Pittsburgh

23298

Virginia Commonwealth University, Richmond

26506

West Virginia University Medical Center, Morgantown

32806

Orlando Health U7 Health Cancer Center, Orlando

37232

Vanderbilt University Medical Center, Nashville

48208

Henry Ford Health System, Detroit

60099

Cancer Treatment Centers of America, Zion

60612

Rush University Medical Center, Chicago

75246

Texas Oncology -Baylor Charles A. Sammons Cancer Center, Dallas

85258

HonorHealth Research Institute, Scottsdale

02114

Massachusetts General Hospital, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Istari Oncology, Inc.

INDUSTRY

NCT04577807 - LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma | Biotech Hunter | Biotech Hunter